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Mice which coexpress human papillomavirus type 16 E7 and HLA A2.1 in peripheral squamous epithelium
and thymic cortical epithelium are tolerant at the cytotoxic T-lymphocyte (CTL) level to E7 epitopes restricted
through HLA A*0201 and H-2b (T. Doan, M. Chambers, M. Street, G. J. Fernando, K. Herd, P. Lambert, and
R. Tindle, Virology 244:352–364, 1998). Here we used bone marrow-reconstituted radiation chimeras to dis-
tinguish whether E7-directed CTL tolerance was mediated peripherally by E7 expression in skin or centrally
by E7 expression in thymus. In chimeric mice expressing E7 in skin and reconstituted with E7-naı¨ve bone
marrow and E7-naı¨ve thymus, CTL responses to vaccine-administered E7 epitopes were not restored, i.e., the
mice remained tolerant. In contrast, chimeric mice not expressing E7 in skin and reconstituted with E7-naı¨ve
bone marrow and E7-expressing thymus had full E7-directed CTL responses. These results demonstrate that
E7 protein expression in peripheral squamous epithelium is sufficient to tolerize the E7-directed CTL precur-
sor repertoire. The data have implications for E7-mediated tumorigenesis and for the development of E7-based
immunotherapeutic strategies, since peripheral immunological tolerance of tumor-associated antigens may
create a barrier to effective immunotherapy.
The E7 oncoprotein of human papillomavirus type 16
(HPV16) is a tumor-specific antigen when expressed in HPV16-
associated cervical epithelial tumors, to which immunomanipu-
lative strategies are being directed, both experimentally (see,
for example, references 7, 9, and 29) and in E7-based thera-
peutic vaccine clinical trials (5). We recently reported studies
with mice expressing HPV16 E7 protein, driven from the ker-
atin 14 (K14) promoter, in basal epithelium of skin and in the
thymic cortex (8). We showed that immunization-induced cy-
totoxic T-lymphocyte (CTL) responses to each of three CTL
epitopes in the E7 protein restricted through two major histo-
compatibility complex (MHC) class 1 haplotypes were down-
regulated in these E7-transgenic mice compared with non-E7
syngeneic control mice. However, in these studies we did not
determine whether the down-regulation (i.e., tolerance) was
induced centrally by E7 expressed in the thymus or peripher-
ally by E7 expressed in epithelium. In the present study, we
distinguish between these two possibilities by specific immuni-
zation of bone marrow-reconstituted thymus-transplanted chi-
meric E7 transgenic mice. We report that chimeric mice ex-
pressing the E7 transgene in peripheral epithelium but not in
the thymus showed E7-specific down-regulated CTL responses
to each of two E7 CTL epitopes restricted through a human
and a mouse MHC class I allele, respectively, when compared
with sham chimeric but non-E7 control mice. In contrast, chi-
meric mice expressing the E7 transgene in thymus, but not
peripheral epithelium, showed E7-directed CTL responses
indistinguishable from those of non-E7 control mice. Thus,
we show that the expression of E7 in peripheral squamous
epithelium is sufficient to induce and maintain a state of tol-
erance against E7.
E7-directed bone marrow-derived precursor CTLs (pCTLs)
are not tolerized in mice expressing E7 in thymus but not in
skin. (K14E7 3 A2.1Kb)F1 mice (designated KA mice) were
derived by crossing male K14.HPV16E7(1/1) mice (16),
which express an HPV16 E7 transgene perinatally and through-
out life in skin and thymic cortical epithelium, with female
HLA A2.1Kb(1/1) mice (30). (FVB 3 A2.1Kb)F1 mice (des-
ignated FA) are syngeneic but do not possess the E7 transgene.
KA (E71) and FA (E72) mice are on an H-2b background. To
inquire whether pCTLs from E7-transgenic mice were toler-
ized on E7-expressing thymus, we constructed thymus-trans-
planted radiation chimeras as described elsewhere (8) from
immunologically depleted FA (E72) mice reconstituted with
KA (E71) bone marrow cells. In half of the mice, [designated
KA3FA(FA) mice], the bone marrow-derived T-cell precur-
sors were made to mature through a thymus implant from an
FA (E72) donor mouse; in the other half of the mice [desig-
nated KA3FA(KA) mice], the bone marrow cells were made
to mature through an E7-expressing KA thymus implant (Fig.
1, panel I). KA3FA(FA) mice, KA3FA(KA) mice, and con-
trol FA (E72) and KA (E71) mice were immunized for CTL
response induction with a mix of peptides containing
82LLMGTLGIV90 (an HLA A*0201-restricted E7 CTL epi-
tope [24]), 49RAHYNIVTF57 (an H-2Db-restricted E7 CTL
epitope [9]), and 58GILGFVFTL66 (an HLA A*0201-restrict-
ed influenza virus matrix CTL epitope [13]). Control mice un-
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derwent surgical procedures but without receiving cell and/or
organ transplants (sham). KA (E71) mice showed the previ-
ously documented (8) down-regulated CTL response to the E7
epitopes (but not to the irrelevant influenza virus matrix epi-
tope) compared to FA (E72) mice (Fig. 1, panels IIC and IID).
In contrast, KA3FA(KA) mice exhibited E7 (and influenza
virus matrix)-directed CTL responses of the same magnitude
as those of KA3FA(FA) mice and FA (E72) mice (Fig. 1,
panels IIA to IIC). These data indicate that E7-directed
pCTLs from E7 transgenic mice which mature through an
E7-expressing thymus, and emerge into a non-E7-expressing
peripheral epithelial environment, are not tolerized.
To eliminate the possibility that bone marrow-derived pre-
cursors from KA (E71) mice had somehow previously encoun-
tered E7 protein before transfer to recipient mice, thereby
influencing their immunological status in the above-described
experiment, we asked whether bone marrow-derived pCTLs
from FA (E72) mice would be tolerized during maturation in
an E7-expressing thymus. We constructed chimeras from im-
munologically ablated FA (E72) mice by reconstitution with
FA (E72) bone marrow cells. In half the mice [designated
FA3FA(KA) mice], the bone marrow cells were made to
mature through an E7-expressing KA thymus implant. In the
other half of the mice [designated FA3FA(FA) mice], the
bone marrow cells were made to mature through a non-E7-
expressing FA thymus implant (Fig. 2, panel I). FA3FA(KA)
mice, FA3FA(FA) mice, and control FA (E72) and KA
(E71) mice were immunized for CTL induction with a mix
of peptides containing the HLA A*0201-restricted and H-2b-
restricted E7 CTL epitopes and influenza virus matrix CTL
epitope. FA3FA(KA) mice exhibited E7-directed CTL re-
sponses of the same magnitude as those of FA3FA(FA) mice
and FA (E72) mice, while KA (E71) mice exhibited the ex-
pected down-regulated E7-directed (but not down-regulated
influenza virus matrix-directed) CTL responses (Fig. 2, panel
II). These data indicated that E7-naı¨ve bone marrow-derived
pCTLs which mature through an E7-expressing thymus and
FIG. 1. (I) Derivation of KA3FA(FA) and KA3FA(KA) chimeric mice
from immunologically ablated FA (E72) mice. (II) CTL responses of splenocytes
from chimeric mice and sham control FA (E72) and KA (E71) mice (three per
group) immunized with a mix of peptides containing E7 CTL epitopes LLMGT
LGIV and RAHYNIVTF and influenza virus matrix CTL epitope GILGFVFTL.
Immunizations were given in Quil A adjuvant and tetanus toxoid as described
elsewhere (8). Spleen cells were restimulated with individual peptides in vitro.
Targets were EL4.A2 cells (8) pulsed with individual peptides as indicated.
EL4.A2 cells are susceptible to specific CTL lysis through both HLA A*0201 and
H-2b restriction elements. CTL assays were conducted as described elsewhere
(8). bm, bone marrow; th, thymus; sk, skin.
FIG. 2. (I) Derivation of FA3FA(FA) and FA3FA(KA) chimeric mice
from immunologically ablated FA (E72) mice. (II) CTL responses of splenocytes
from chimeric mice and sham control mice (three per group) immunized with a
mix of peptides containing E7 CTL epitopes LLMGTLGIV and RAHYNIVTF
and influenza virus matrix CTL epitope GILGFVFTL. Spleen cells were restim-
ulated with individual peptides in vitro. Targets were EL4.A2 cells pulsed with
individual peptides as indicated. CTL assays were conducted as described else-
where (8). bm, bone marrow; th, thymus; sk, skin.
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emerge into a non-E7 peripheral epithelial environment are
not tolerized to E7.
Bone marrow-derived pCTLs are specifically tolerized in
mice expressing E7 in skin but not in thymus. To inquire
whether E7-directed pCTLs were tolerized in mice expressing
E7 in skin but not in thymus, we constructed chimeric mice in
which bone marrow-derived precursors were made to mature
through a non-E7-expressing thymus and to emerge into an
E7-expressing peripheral epithelial environment. In a first ex-
periment, immunologically ablated KA (E71) mice were re-
constituted with KA (E71) bone marrow cells which were
made to mature through a thymus implanted from an FA
(E72) mouse. The recipient mice, designated KA3KA(FA)
(Fig. 3, panel I), and control FA (E72) and KA (E71) mice
were immunized for CTL response induction with a mix of
peptides containing the HLA A*0201-restricted and H-2b-re-
stricted E7 CTL epitopes and the influenza virus matrix CTL
epitope. In KA3KA(FA) mice, E7-directed CTL responses to
both E7 epitopes were down-regulated to the level seen in
control KA (E71) mice (Fig. 3, panel IIB), while control FA
(E72) mice showed the expected high responses to both E7
CTL epitopes.
In a second experiment, immunologically ablated KA (E71)
mice were reconstituted with bone marrow from FA (E72)
mice, which was made to mature through a non-E7-expressing
FA thymus. These mice, designated FA3KA(FA) mice (Fig.
4, panel I), were immunized for CTL response induction with
a mix of peptides containing the HLA A*0201-restricted and
the H-2b-restricted E7 CTL epitopes and the influenza virus
matrix CTL epitope. As with KA3KA(FA) mice in the pre-
vious experiment, E7-directed CTL responses to both E7 epi-
topes were down-regulated as in KA (E71) controls and in
contrast to FA (E72) controls, while the influenza virus matrix
response confirmed adequate reconstitution.
The results from these two experiments indicate that bone
marrow-derived E7-directed pCTLs which mature through a
FIG. 3. (I) Derivation of KA3KA(FA) chimeric mice from immunologically
ablated KA (E71) mice. (II) CTL responses of splenocytes from chimeric mice
and sham control mice (three per group) immunized with a mix of peptides
containing E7 CTL epitopes LLMGTLGIV and RAHYNIVTF and influenza
virus matrix CTL epitope GILGFVFTL. Spleen cells were restimulated with
individual peptides in vitro. Targets were EL4.A2 cells pulsed with individual
peptides as indicated. CTL assays were conducted as described elsewhere (8).
bm, bone marrow; th, thymus; sk, skin.
FIG. 4. (I) Derivation of FA3KA(FA) chimeric mice from immunologically
ablated KA (E71) mice. (II) CTL responses of splenocytes from chimeric mice
and sham control mice (three per group) immunized once with a mix of peptides
containing E7 CTL epitopes LLMGTLGIV and RAHYNIVTF and influenza
virus matrix CTL epitope GILGFVFTL. Spleen cells were restimulated with
individual peptides in vitro. Targets were EL4.A2 cells pulsed with individual
peptides as indicated. CTL assays were conducted as described elsewhere (8).
bm, bone marrow; th, thymus; sk, skin.
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non-E7-expressing thymus and emerge into an E7-expressing
epithelial environment are specifically tolerized to E7.
We have previously reported pCTL tolerance to epitopes of
the HPV16 E7 oncoprotein in KA mice expressing a K14
promoter-driven E7 transgene perinatally and throughout life
in the thymus and in basal and/or suprabasal cells of peripheral
epithelium (8). In the present experiments, we demonstrate
that the E7-directed pCTL repertoire is tolerized in mice ex-
pressing E7 in peripheral epithelium in the absence of thymic
expression. Conversely, the repertoire is not tolerized in mice
expressing E7 in the thymus, in the absence of E7 expression in
peripheral epithelium. These data indicate that expression of
E7 in peripheral epithelium, and not the thymus, is sufficient to
induce and maintain a state of pCTL tolerance to E7. In the
thymus, the K14 promoter directs transgene expression to the
cortical epithelial compartment (19), which, in other mouse
models, has been shown to contribute to the shaping of the
T-cell repertoire by positive rather than negative selection (for
example, see reference 20). Melero et al. (21) observed no
functional down-regulation of the CTL responses induced by
immunization with E7 peptide epitope RAHYNIVTF in H-2b
mice expressing HPV16 E7 from a K14 promoter and con-
cluded that the mice remain immunologically ignorant of this
epitope. This result contrasts with ours. Together, they provide
further examples of T-cell tolerance to peripheral antigens in
some systems (see, for example, references 1, 2, and 23) and
T-cell ignorance in others (see, for example, references 14, 17,
and 25). While determinants of immunological outcome of
peripheral antigen expression are clearly complex (22), the
level of expression (as well as timing and site of expression) can
determine whether an antigen induces tolerance or is ignored
by naı¨ve T cells. This consideration may explain the difference
between the results of Melero et al. and ours. The effect of the
level of E7 expression on peripheral tolerance induction is
under investigation in our laboratory.
Specific CTL tolerance has implications for E7-mediated
tumorigenesis. Nascent E7-expressing tumor cells will escape
surveillance where little or no positive priming of cognate
pCTLs by endogenous E7 occurs. Additionally, specific CTL
tolerance which inhibits the generation of an immunization-
induced CTL response will detract from effective immunother-
apy (26). We have previously reported that (K14.E7 3 C57)F1
mice fail to control a challenge with an E7-expressing tumor
following immunization with E7 CTL epitope RAHYNIVTF,
whereas in immunized non-E7-transgenic control mice the tu-
mors did not become established (12). Failure to control the
tumor was correlated with a lack of an inducible RAHYNI
VTF-directed CTL response in E7-transgenic mice, in contrast
to non-E7-transgenic control mice, where a powerful CTL
response was observed. In further experiments, multiple im-
munization of KA mice with E7 CTL epitopes or whole E7
protein failed to arrest the development of E7-associated en-
dogenous tumors (8), again being correlated with a lack of
E7-directed CTL responses.
The current therapeutic vaccine strategy for HPV16-associ-
ated cervical carcinoma targets the E7 tumor-specific antigen
by CTL induction (5, 28). The possibility arises that chronic
expression of E7 in transformed cervical epithelial cells during
the life of the tumor functionally tolerizes E7-directed pCTLs.
Ongoing experiments in our laboratory will distinguish be-
tween presentation of E7 to pCTLs directly by keratinocytes
and cross presentation of exogenously acquired E7 by bone
marrow-derived professional antigen-presenting cells. Presen-
tation of antigen by either of these routes can be tolerogenic
(3, 6, 15, 27). Additionally, we will determine whether loss of
functional E7-directed CTLs results from pCTL deletion (4,
11) or anergy (10, 25). Peripheral tolerance of tissue-specific
antigen depends, at least in some cases, on the generation of
regulatory CD41 cells (see, for example, reference 18). That
E7-directed CTL tolerance in KA (E71) mice reflects an im-
pairment of cognate CD41 help is unlikely in view of our
finding that (K14.E7 3 C57)F1 mice immunized with full-
length E7 and displaying E7-specific pCTL tolerance showed
concomitant enhanced E7-directed CD41 T-helper responses
(12).
The data reported in the present study demonstrate the
induction of peripheral tolerance in E7-directed pCTLs by
HPV16 E7 expressed in squamous epithelial cells, in the con-
text of human (and mouse) MHC class 1 haplotypes. There are
direct implications for the development and progression of
cervical cancers which express E7 in transformed squamous
epithelium and for the design of E7-based immunotherapeutic
strategies for cervical cancer. In the broader context, there are
implications for CTL response induction to any foreign or
aberrant protein expressed constitutively in squamous epithe-
lial cells as a result of infection, tumorigenesis, or appearance
of autoantigen.
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